What Burana Treats: Main Uses and Benefits

Burana is commonly used across therapeutic domains where the primary patient need is short-term supportive relief from pronounced or disruptive symptoms. This supportive relief generally helps patients cope more steadily with symptom fluctuations, contributing to improved day-to-day comfort during periods of heightened symptoms. In clinical and home care contexts, Burana (Ibuprofen) is utilized where short-term symptom management is appropriate, addressing symptoms of discomfort, heightened physiological activity, and irritative states.

The medication is relevant for easing symptoms related to physical discomfort, encompassing various acute or episodic changes such as headaches, musculoskeletal pain, dental pain, and the cramping associated with menstrual pain. It is also applied when symptoms are related to inflammatory or irritative states, notably the stiffness and tenderness seen in conditions like osteoarthritis and sprains. Furthermore, it plays a role in managing fever and generalized malaise during seasonal illnesses.

Quick Fact: Relief for Pain, Fever, and Inflammation The core benefit of Burana is providing supportive relief that assists with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Burana?

The population eligibility for Burana (Ibuprofen) is strictly defined by official regulatory labeling, outlining specific groups for whom use is prohibited, restricted, or conditional.

Absolute Contraindications

Use is contraindicated in patients with known hypersensitivity to Ibuprofen, Aspirin, or other NSAIDs. The medicine must not be used by individuals with active gastrointestinal bleeding or a history of recurrent peptic ulcers. Absolute non-eligibility also applies to patients with severe heart failure (NYHA Class IV), severe renal failure, or severe hepatic failure. Use is also prohibited during the third trimester of pregnancy and for the management of peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery.

Conditional and Restricted Use

Certain populations are eligible only under conditional restrictions, mandating the use of the lowest effective dose for the shortest duration. This includes elderly patients and those with mild-to-moderate renal or hepatic impairment. Patients with uncontrolled hypertension or congestive heart failure (NYHA Class II-III) must use caution, and high doses (ge2400 mg/day) are to be avoided. Eligibility is generally established for adults and adolescents (ge12 years); however, children under 6 years of age or 20 kg are typically contraindicated for most solid dose forms.

Burana (Ibuprofen) exhibits several officially documented interactions based on authoritative regulatory labeling. The co-administration of Burana is contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery, and use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) must be avoided due to additive risks.

Documented Pharmacodynamic and Exposure Interactions

Interacting Substance/Class	Documented Outcome
Anticoagulants/Corticosteroids	Increased risk of serious gastrointestinal bleeding.
Low-Dose Aspirin	May competitively inhibit the antiplatelet effect.
Antihypertensives (ACEi, ARBs)	May diminish the blood pressure-lowering effect.
Lithium, Methotrexate	Clearance is reduced, leading to elevated plasma levels.

Interaction-Related Constraints

The product label establishes specific constraints for administration. For immediate-release low-dose aspirin, regulators recommend a dose timing separation of at least 8 hours before or 30 minutes after aspirin to minimize the documented pharmacodynamic interference. Furthermore, consumption of three or more alcoholic drinks daily while using the product is officially documented to increase the risk of GI bleeding. Population-specific cautions note that elderly patients and those with pre-existing renal, cardiac, or hepatic impairment face a greater risk of adverse events when co-administering with drugs such as ACE Inhibitors.

Targeting the Prostaglandin Synthesis Pathway

Burana (Ibuprofen) functions by the competitive, reversible inhibition of the Cyclooxygenase (COX) enzymes, affecting both the COX-1 and COX-2 isoforms. By blocking the active site, Ibuprofen restricts the conversion of arachidonic acid into prostanoid precursors, initiating a signaling cascade that modulates pathways mediated by eicosanoids. This action restricts the formation of eicosanoids that influence inflammatory and thermoregulatory signaling, such as PGE2.

---

️ Central and Peripheral Physiological Modulation

The reduced synthesis of PGE2 alters two key physiological control systems. Centrally, the lack of PGE2 in the hypothalamus reverses the elevation of the central thermal set point. Peripherally, the decreased mediator concentration at injury sites decreases the excitability of peripheral nociceptors. This dual action on temperature regulation and peripheral sensory signaling influences physiological feedback mechanisms that regulate excessive mediator activity.

Administration Guidelines: How to Use Ibuprofen (Burana)

Official instructions for the use of Ibuprofen, the active ingredient in Burana, govern the administration route, dose range, frequency, and timing. Standardized administration protocols ensure consistent usage across different formulations.

Administration Scope	Official Instruction (Label-Based)
Route of Administration	Primarily Oral (tablet, capsule, liquid suspension) and Rectal (suppository). Specialized intravenous (IV) forms are used in hospital settings.
Dosing Schedule (Adults)	Non-prescription doses are typically 200 mg to 400 mg per administration. The maximum daily dose for non-prescription use is 1200 mg. Prescription regimens for chronic conditions utilize higher maximum daily limits in divided doses.
Frequency and Timing	Dosing intervals are generally every 4 to 6 hours as needed. For chronic use, doses are typically divided and administered 3 to 4 times daily.
Context of Administration	Oral forms should be taken with or immediately after food or milk to comply with labeled consumption instructions. Oral suspensions must be shaken and accurately measured.
Duration of Use	Use for self-treatment of fever is often officially limited to 3 days and for pain to 7 to 10 days. Prolonged use requires professional determination.
Age-Group Rules	Pediatric dosing is calculated based on body weight (e.g., 5 to 10 mg/kg per dose), not age alone. Older adults are advised to use the lowest effective dose.

---

Resulting Procedural Structure

The official protocol requires that the medicine be administered at the correct labeled dose and frequency, with the primary instruction being administration with or after food. The use pattern is structured as intermittent and short-term, unless the product is prescribed for a chronic inflammatory condition, which follows a different regimen. If a dose is missed, individuals on an as-needed schedule should resume the next dose when required, and those on a regular schedule should not take a double dose, adhering strictly to the mandated dosing interval.

Research Evidence / Overview of Studies for Burana

---

Evidence for Use in Acute Symptom Relief (Pain and Fever)

Research for the active ingredient in Burana, Ibuprofen, has primarily focused on studies evaluating outcomes related to symptom intensity and physiological measurements. These investigations involve large numbers of short-term, randomized controlled trials (RCTs) where the agent was studied for episodic symptom patterns, such as headaches, dental pain following surgery, and the cramping associated with menstrual discomfort. The studies included adult and adolescent participants experiencing phases of heightened symptom activity.

These research trials explored how symptom intensity or variability changed over short periods, typically just a few hours post-administration. The findings describe patterns observed in the studies regarding the data points recorded for pain scores reported by groups of participants when compared to a placebo or other agents studied in the same trials. Because these studies are designed to focus on acute episodes, the follow-up durations were limited.

---

Evidence for Use in Chronic Inflammatory Conditions

Research has been conducted in settings involving longer-lasting conditions characterized by cycles of stability and flare-ups, such as osteoarthritis and certain musculoskeletal sprains. These investigations often include intermediate-term RCTs, typically lasting only a few weeks, as well as longer-term observational settings evaluating daily-life functioning.

These trials primarily monitor outcomes reflecting daily functioning or activity level, using specialized scales like the WOMAC index to observe joint pain, stiffness, and ability to perform routine physical tasks. The findings describe patterns observed in the studies regarding the data points recorded for functional scores over the study period. However, research focusing solely on effectiveness outcomes rarely extends beyond four weeks, meaning the long-term stability of measured functional outcomes over many months or years is not fully established.

---

Areas of Research Uncertainty and Evidence Gaps

Follow-up durations were limited in many of the foundational efficacy trials, meaning that long-term effects are not fully established regarding sustained functional outcomes. Additionally, data for certain groups remain insufficient, particularly in adults with complex, multiple concurrent conditions. Overall, the research describes group patterns, not personal outcomes, and the certainty regarding specific responses in every possible clinical scenario remains low.

Common questions about Burana (FAQ)

Q: What is Burana and how does it work?

A: Burana is a brand name for the non-steroidal anti-inflammatory drug (NSAID) ibuprofen.

It works by blocking the production of certain natural substances in the body that cause inflammation, pain, and fever. By reducing these substances, ibuprofen helps to lower fever and ease pain and inflammation.

Q: What is Burana used for?

A: Burana is used to relieve a variety of symptoms, including:

• Mild to moderate pain, such as headaches, muscle aches, dental pain, and menstrual cramps.
• Fever
• Pain and inflammation associated with conditions like arthritis and juvenile arthritis.
• Pain related to the common cold or flu.

Q: How quickly does Burana start working?

A: The pain-relieving effects of Burana (ibuprofen) can usually begin within 30 minutes to 1 hour after taking a dose.

For fever reduction, the effect may also start within the hour. The full effect for pain or inflammation may take longer, especially in chronic conditions.

Q: Who should not take Burana?

A: You should generally avoid taking Burana (ibuprofen) if you have certain medical conditions, including:

• A known allergy to ibuprofen, aspirin, or other NSAIDs.
• A history of asthma, hives, or allergic-type reactions after taking aspirin or other NSAIDs.
• Active or recent stomach or intestinal bleeding (ulcers or perforation).
• Severe heart failure or severe kidney failure.
• In the last three months of pregnancy.

If you have high blood pressure, heart disease, liver or kidney problems, or are elderly, consult your healthcare provider before use.

Q: Can Burana be taken with other pain relievers?

A: It is not recommended to take Burana (ibuprofen) with other NSAIDs, such as naproxen or aspirin (unless a low-dose aspirin is taken under a doctor’s supervision for a heart condition), as this increases the risk of serious side effects like stomach bleeding.

You can generally take Burana with acetaminophen (a non-NSAID pain reliever) if instructed by a healthcare professional, as they work differently and do not have the same risk of combined side effects.

How to Store and Dispose of Burana (Ibuprofen)

The storage of Burana (ibuprofen) is governed by specific regulatory requirements to ensure product stability.

---

Official Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C), avoiding excessive heat above 40 C and freezing.
Protection	Keep in a tight container and protect from light and moisture.
Safety	Must be stored out of the sight and reach of children.

---

Disposal Instructions

Any unused or expired medicine must be handled in accordance with local requirements established by waste management authorities. Official documents instruct that the product should not be disposed of in wastewater or household waste to prevent environmental harm; some directions specify returning unused medicine to a pharmacist for proper disposal.